Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06741085
What this trial is testing

Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)UnknownNCT03050437
What this trial is testing

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Samsung Medical Center 96
Testing effectiveness (Phase 2)Study completedNCT02616393
What this trial is testing

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Who this might be right for
Non-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases
Kadmon Corporation, LLC 36
Large-scale testing (Phase 3)Study completedNCT01667562
What this trial is testing

Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 375
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Not applicableStudy completedNCT02751879
What this trial is testing

Real World Data on Gi(l)Otrif® Dose Adjustment

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 228
Testing effectiveness (Phase 2)Ended earlyNCT00748709
What this trial is testing

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Who this might be right for
Neoplasms
Boehringer Ingelheim 20
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Testing effectiveness (Phase 2)Study completedNCT03940703
What this trial is testing

Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Who this might be right for
Non-small Cell Lung Cancer
EMD Serono Research & Development Institute, Inc. 140
Testing effectiveness (Phase 2)Study completedNCT02544997
What this trial is testing

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Who this might be right for
Metastatic Breast Cancer
Samsung Medical Center 5
Testing effectiveness (Phase 2)Study completedNCT01562028
What this trial is testing

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Who this might be right for
Lung Cancer
ETOP IBCSG Partners Foundation 109
Testing effectiveness (Phase 2)UnknownNCT03341494
What this trial is testing

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Who this might be right for
NSCLC Stage IVChemotherapy Effect
Fujian Cancer Hospital 128
Not applicableLooking for participantsNCT05257967
What this trial is testing

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Who this might be right for
EGFR Activating MutationLeptomeningeal MetastasisNon Small Cell Lung Cancer
British Columbia Cancer Agency 10
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778149
What this trial is testing

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Who this might be right for
AumolertinibAnlotinibTP53+2 more
Tianjin Medical University Cancer Institute and Hospital 47
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Not applicableStudy completedNCT01167972
What this trial is testing

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 2,000
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Testing effectiveness (Phase 2)Study completedNCT03544814
What this trial is testing

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Shanghai Chest Hospital 99
Testing effectiveness (Phase 2)Active Not RecruitingNCT04545710
What this trial is testing

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
Lung Cancer
University of California, San Diego 18
Next Page